Exposing the Middlemen in Rising Drug Costs: Modifying Safe Harbor Protections for Pharmacy Benefit Manager Rebates Under Federal Anti-Kickback Statues
| dc.contributor.author | Gore, Abigail | |
| dc.date.accessioned | 2020-01-21T18:22:34Z | |
| dc.date.available | 2020-01-21T18:22:34Z | |
| dc.date.issued | 2020-01-18 | |
| dc.description | 28 pages | en_US |
| dc.description.abstract | Pharmacy Benefit Managers (PBMs) have, until very recently, largely escaped public scrutiny or possibly even public consciousness. Although relatively unknown to the average American healthcare consumer, specialized healthcare companies known as PBMs play a direct role in negotiatinegotiating pharmaceutical drug prices for more than 266 million Americans. Rising pharmaceutical costs, on the other hand, invaded the public consciousness in 2016 when a dramatic increase in the price of pharmaceutical company Mylan’s EpiPen sparked outrage across the country. | en_US |
| dc.identifier.citation | 98 OR. L. REV. 297 | en_US |
| dc.identifier.issn | 0196-2043 | |
| dc.identifier.uri | https://hdl.handle.net/1794/25139 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | University of Oregon School of Law | en_US |
| dc.rights | All Rights Reserved. | en_US |
| dc.subject | Pharmaceutical drug prices | en_US |
| dc.subject | Federal regulation | en_US |
| dc.subject | Healthcare | en_US |
| dc.subject | Pharmacy Benefit Managers | en_US |
| dc.subject | Drug rebate pricing | en_US |
| dc.title | Exposing the Middlemen in Rising Drug Costs: Modifying Safe Harbor Protections for Pharmacy Benefit Manager Rebates Under Federal Anti-Kickback Statues | en_US |
| dc.type | Article | en_US |